We estimate Revenue/EBITDA/PAT CAGR of 11%/14%/15% over CY22-25E based on the above thesis and we maintain our BUY rating on the stock with the unchanged TP of Rs 22,000/share. We value the company at 65x CY24 EPS. The TP implies an upside of 12% from the CMP.